AMPLO BIOTECHNOLOGY
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
AMPLO BIOTECHNOLOGY
Industry:
Biotechnology Health Care Neuroscience Therapeutics
Founded:
2019-01-01
Address:
Pompano Beach, Florida, United States
Country:
United States
Website Url:
http://www.amplobiotechnology.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.24 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon LetsEncrypt SSL By Default HSTS Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
NIAMS
NIAMS investment in Grant - Amplo Biotechnology
National Institutes of Health
National Institutes of Health investment in Grant - Amplo Biotechnology
Casdin Capital
Casdin Capital investment in Seed Round - Amplo Biotechnology
BioBrit
BioBrit investment in Seed Round - Amplo Biotechnology
SeedFolio
SeedFolio investment in Seed Round - Amplo Biotechnology
Official Site Inspections
http://www.amplobiotechnology.com Semrush global rank: 13.18 M Semrush visits lastest month: 78
Unable to get host informations!!!
More informations about "Amplo Biotechnology"
Amplo Biotechnology
Amplo is developing gene therapies (AAV) for diseases affecting the neuromuscular junction (e.g. congenital myasthenia, ALS, ageing, myasthenia gravis)See details»
Amplo Biotechnology - Crunchbase Company Profile
Contact Email [email protected] Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop …See details»
Amplo Biotechnology, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Amplo Biotechnology, Inc. of Towson, MD. Get the latest business insights from Dun & Bradstreet.See details»
Amplo Biotechnology Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Amplo Biotechnology. Use the PitchBook Platform to explore the full profile.See details»
Amplo Biotechnology Company Profile | Management and
[email protected]: Amplo Biotechnology Top Competitors. Company Employees Revenue Top technologies; Q Therapeutics Inc. 12: $3.5 M: Osage University Partners. 16: …See details»
Amplo Biotechnology - VentureRadar
"Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, …See details»
Amplo Biotechnology - Overview, News & Similar companies
May 28, 2023 Who is Amplo Biotechnology. Amplo Biotechnology is a leading late-stage preclinical AAV gene therapy company, committed to leveraging gene therapy advancements …See details»
Amplo Biotechnology Company Profile: Overview and Full News …
Amplobiotechnology.com. Overview: Amplo Biotechnology. Amplo Biotechnology, located in Florida, is a company focused on developing gene therapy solutions for diseases of the …See details»
Amplo Biotechnology - Products, Competitors, Financials, …
Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress. Oct 17, 2024. News provided by Share this article Share toX …See details»
Amplo Biotechnology - Company Profile - Tracxn
Nov 17, 2024 Amplo Biotechnology ranks 237th among 473 active competitors. 169 of its competitors are funded while 104 have exited. Overall, Amplo Biotechnology and its …See details»
Amplo Biotechnology - VentureRadar
Similar Companies: NMD Pharma Denmark Privately Held NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by …See details»
Amplo Biotechnology Closes Series Seed Financing to Advance …
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for …See details»
Amplo Biotechnology Secures Fast Track STTR Funding for AMP …
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular …See details»
Amplo Biotechnology Secures Fast Track STTR Funding for AMP
SAN DIEGO, May 29, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular …See details»
Amplo Biotechnology Secures Fast Track STTR Funding for AMP …
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular …See details»
Amplo Biotechnology Secures Fast Track STTR Funding for AMP …
May 29, 2023 In the news release, Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency, is...See details»
Amplo receives NIH-NIAMS grant for gene therapy AMP-201
AMP-201 addresses the severe congenital myasthenic syndrome (CMS) caused by collagen Q (ColQ) deficiency. As part of an exclusive licensing agreement, Amplo Biotechnology secured …See details»
Amplo Biotechnology Closes Series Seed Financing to Advance …
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for …See details»
AMP-101 Shows Pharmacologic and Safety Promise for ... - CGTlive™
Mar 23, 2023 According to the findings of a pharmacology and safety analysis of AMP-101, Amplo Biotechnology’s investigational gene therapy for the treatment of neuromuscular …See details»
Amplo Biotechnology Secures Fast Track STTR Funding for AMP …
SAN DIEGO, May 29, 2023 /PRNewswire/ — Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular …See details»